Newsfiscal.ai
Visara, Inc. Enters Option Agreement for YOL104 Program
· Published
Article summary
Visara, Inc., a majority-owned subsidiary of NovaBridge Biosciences, has secured an exclusive option to acquire worldwide rights to the YOL104 program for the treatment of Ocular Surface Squamous Neoplasia.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…